ReviewImmunotherapy2025
The potential of CAR T cells in autoimmune diseases.
Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CAR-T therapy for immune-mediated necrotizing myopathy: a review of mechanisms and emerging clinical evidence.Clinical rheumatology · 2026Review
- Chimeric Antigen Receptor T-cell (CAR-T) Therapy in Autoimmune Diseases: A Narrative Review.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CAR T cell therapy represents an emerging, promising approach in the field of autoimmune diseases. Unlike monoclonal antibodies, CAR T cells offer a deeper B cell depletion than monoclonal antibodies through their ability to infiltrate tissues and their independence from effector mechanisms. Early data from case reports and phase I/II studies demonstrate encouraging clinical responses in patients with severely refractory autoimmune disorders. CD19, BCMA and dual-targeting CAR constructs were generally well tolerated with limited safety concerns. This promising data encourages further research investigating CAR T cell therapy in a broader range of autoimmune indications and to advance CAR T constructs to improve efficacy, safety, and clinical application. In this review, we explore the rationale of using CAR T cell therapy in autoimmune diseases, summarize relevant clinical data, and highlight future perspectives within the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.